retatrutide phase 3 results Lilly orforglipron oral GLP-1 weight loss trial Eli Lilly infiltrates anti-obesity market

GLP-1s and Addiction The authors of GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer , appearing in October 2025 in JES, point out that the World Health Organization reported 890 million adults and 60 million children and adolescents had obesity in 2022 globally

The GLP-1 analogs, semaglutide and liraglutide, delay the progression of atherosclerosis by regulating inflammatory pathways in low-density lipoprotein receptor-deficient (LDLr -/- ) and apolipoprotein E-deficient (ApoE -/- ) mice [16]

, : ( ) ( , , ( ) ( ) - , , -, -

Many patients experience fatigue during initial months

In a recent eight-year study, DeFronzo demonstrated that insulin-resistant individuals with normal glucose tolerance were at high risk for future diabetes and cardiovascular events such as heart attack and stroke

Researchers investigate how Retatrutide may interact with cellular pathways that coordinate metabolic responses within endocrine tissues